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PCV34
Statin USe and RiSk Of deVelOPing diabeteS in CaRdiOVaSCUlaR 
diSeaSe: SyStematiC liteRatURe ReView and meta-analySiS
Thakker D., Nair S.R., Shukla H, Shaikh J.S.
Capita India Pvt. Ltd., Mumbai, India
Objectives: Statins are widely used for the primary and secondary prevention 
of cardiovascular diseases (CVDs). Studies have shown that statins may induce 
diabetes in non-diabetic CVD patients, as class effect. This systematic literature 
review aims to evaluate the risk of developing diabetes in CVD patients receiving 
statins. MethOds: Randomized controlled trials (RCTs), which used any statin as 
an intervention for non-diabetic CVD patients, were identified from August 2010 
to June 2014 in databases such as, Embase, PubMed, and Cochrane. The timeframe 
of the searches was selected post the study conducted by Mills et al. in 2011. This 
review will also include relevant studies from the Mills et al. study until August 2010. 
Two researchers will independently review studies as per the Cochrane method-
ology for systematic reviews. The primary outcome is the incidence of diabetes. 
Subgroup analyses will also be performed to assess whether statin type, age, eth-
nicity or patient groups contribute to the intensity of the risk of developing dia-
betes. Results: In total, 5238 potentially relevant studies were retrieved from the 
databases and are being screened for inclusion in the review. The data extraction 
and analyses (both qualitative and quantitative) are being performed and the full 
results will be presented in the poster. cOnclusiOns: This systematic literature 
review is an update of the findings of a previous study and will hopefully throw 
more light on the association between statin use and the risk of diabetes in CVD 
patients, with special emphasis on subgroups.
PCV35
a RetROSPeCtiVe StUdy Of mORtality in RiSk PatientS with high dOSe 
Statin USage and nO Statin USage
Rockberg J.1, Jørgensen L.1, Taylor B.2, Kilpatrick R.D.2, Sobocki P.1
1Pygargus/IMS Health, Stockholm, Sweden, 2Amgen Inc, Thousand Oaks, CA, USA
Objectives: The aim of this retrospective cohort study was to calculate hazard 
rates of CV/non-CV related death in risk patients stratified by statin dose and to 
generate data for health-economic analyses. MethOds: Anonymous retrospective 
electronic medical records were extracted from a 10% sample of the Swedish popula-
tion > 18 years in primary care and merged with hospital records, prescribed drugs, 
and death data by National Board of Health and Welfare. Cohorts were defined as 
diabetic (DM), Clinically-evident CardioVascular Disease (CeCVD), Acute Coronary 
Syndrome (ACS), Heart Failure (HF) and Ischemic Stroke (IS) patients. CV/non-CV 
related death was investigated. The population was divided into high dose statin 
users (> 40 mg simvastatin or equivalent) and non-statin users. Royston Parmar (RP) 
spline analysis was used to calculate hazard rates of both outcomes in each cohort 
to enable a smooth hazard function with good fit to data compared to ordinary Cox 
regression. Initial AIC-based optimization demonstrated that modeling of the log 
cumulative odds as a spline function of log time and three nodes gave the best fit. 
Crude rates were calculated for each cohort and event, and hazard rates adjusted 
for gender, diabetes, LDL (where applicable) and age were calculated. Results: 
The total database consisted of 1.3 million patients; there were 55,778 DM, 47,581 
CeCVD, 49,857 ACS, 82,835 HF and 38,949 IS patients. High dose statin users showed 
after initial decrease a constant/marginally increasing hazard rate, whereas the no 
statin group after initial decrease had a strong increase in hazard rate versus time. 
The overall hazard rate was always higher for the no statin group. Independent of 
statin status diabetics and males demonstrated an at least numeric elevated hazard 
rate. cOnclusiOns: RP splines could be used to generate hazard rate functions 
for cost-effectiveness models. The death rate was lower in patients with high dose 
statin usage.
CaRdiOVaSCUlaR diSORdeRS – Cost Studies
PCV36
bUdgetaRy imPaCt analySiS Of ReimbURSement VaReniCline in the 
SmOking CeSSatiOn tReatment Of PatientS with CaRdiOVaSCUlaR 
diSeaSeS, ChROniC ObStRUCtiVe PUlmOnaRy diSeaSe OR tyPe-2 diabeteS 
mellitUS: a natiOnal health SyStem PeRSPeCtiVe in SPain
Rejas Gutiérrez J.1, Sicras Mainar A.2, Navarro Artieda R.3, De Lossada Juste A.4
1Pfizer S. L. U., Alcobendas/Madrid, Spain, 2Badalona Serveis Assistencials SA, Badalona 
(Barcelona), Spain, 3Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain, 4Pfizer, S. L. U, 
Alcobendas/Madrid, Spain
Objectives: Varenicline is indicated for smoking cessation. Around 60.000 peo-
ple die every year in Spain because of tobacco related diseases, particularly car-
diovascular diseases (CVD), chronic obstructive pulmonary disease (COPD) and 
type-2 diabetes mellitus (t2DM). At present, varenicline is not reimbursed in the 
Spanish National Health System (NHS). The objective was to estimate the budgetary 
impact (BI) for the NHS of the reimbursement of varenicline in smoking cessation 
in patients with CVD, COPD or t2DM. MethOds: BI was estimated comparing the 
actual not-reimbursed scenario versus a reimbursed scenario using the Spanish 
NHS perspective. A hybrid BI model was designed using epidemiological data to 
estimate size of populations and a Markov modelling simulating until four quit-
ting attempts to estimate smoking cessation rates with varenicline during a 5-year 
horizon. Costs of cessation attempts were considered in the reimbursement sce-
nario only, and included varenicline, medical visits and counselling. Effectiveness 
of varenicline was expressed as one year of abstinence rate following a 12-weeks 
course of standard doses, and were derived from clinical trials. Cost savings due to 
smoking cessation were extracted from local published cost-of-illness studies in 
such populations. Results showed incremental cost-savings of reimbursed versus 
not reimbursed scenario. Univariate sensitivity analysis was also applied. Results: 
Five-years cumulated cessation attempts increased from 140,795 in the not-reim-
bursed to 354,631 in the reimbursed scenario, yielding to 52,127 extra subjects 
PCV29
the aSSOCiatiOn between the natURe and timing Of dental ViSitS 
and C-ReaCtiVe PROtein leVelS
Candrilli S.D.1, Blackwood J.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Danbury Hospital, Danbury, CT, USA
Objectives: Evidence suggests an association between dental disease and car-
diovascular disease (CVD). C-reactive protein (CRP), an inflammatory marker, has 
been implicated as a risk factor for CVD, and dental disease can affect CRP levels. 
Our study examined the relationship between the timing and nature of dental 
visits and CRP. MethOds: Using data from the US-based 1999-2000, 2001-2002, 
and 2003-2004 National Health and Nutrition Examination Surveys, we examined 
the relationship between time since and reason for most recent dental visit and 
CRP among adults ≥ 20 years old. Participants were excluded if they were pregnant 
at the time of the survey, did not take part in the examination component of the 
survey, or were missing covariates for a logistic regression model: age, sex, race, 
BMI, HbA1c, WBC count, CRP measure, time since and reason for last dental visit, 
smoking status, cholesterol-lowering medication use, and history of asthma, cancer, 
rheumatoid arthritis, chronic bronchitis, or recent illness. A dichotomous elevated 
CRP measure was used, defined as CRP > 0.30 mg/dL. Time since last dental visit 
was categorized as < 6 months, 6 months to < 1 year, 1 year to < 2 years, and 2+ 
years ago; respondents who reported never visiting a dentist were placed in the 
2+ years category. Results: A greater proportion of the normal (≤ 0.30 mg/dL) CRP 
group last visited a dentist < 6 months ago (P= 0.0460), and last visited the dentist 
for a “preventive” visit (P< 0.0001), while a greater proportion of the elevated CRP 
group last visited the dentist for a “symptom-driven” visit (P< 0.0001). Regression 
model results demonstrated that preventive visits are associated with a reduced 
likelihood of elevated CRP (OR= 0.722; P= 0.0120), regardless of the time since last 
visit. cOnclusiOns: Given the apparent association between risk of elevated CRP 
and reason for the last dental visit, medical and dental providers should consider 
interventions specifically around appropriate dental care.
PCV30
tRaditiOnal and nOn-tRaditiOnal RiSk faCtORS fOR CaRdiOVaSCUlaR 
diSeaSe in tyPe 2 diabeteS: SyStematiC ReView Of lOngitUdinal 
StUdieS
Smith-Palmer J.1, Bae J.P.2, Boye K.S.2, Perez-Nieves M.2, Valentine W.J.1
1Ossian Health Economics and Communications, Basel, Switzerland, 2Eli Lilly and Company, 
Indianapolis, IN, USA
Objectives: A systematic literature review of longitudinal studies across a broad 
range of both general and disease specific populations was performed to understand 
characteristics of patients with type 2 diabetes (T2D) with risk factors for cardiovas-
cular (CV) events and whether the magnitude of CV risk varies across different T2D 
populations. MethOds: MeSH term based literature searches were performed in 
the PubMed, EMBASE and Cochrane Library databases. For inclusion, studies (in any 
disease area) were required to have a minimum of 1,000 T2D patients and minimum 
5 years follow up. After 2 rounds of review a total of 52 articles and 2 meta-analyses 
were included. Results: Twenty nine articles were described as prospective studies; 
13 articles were from Europe, 20 from Asia Pacific, 13 from North America, 2 from the 
Middle East and 4 were multinational. Six articles were sourced from general or non-
diabetes specific data and 46 articles were based on diabetes studies. Several publica-
tions were from large scale diabetes registries (e.g. Hong Kong Diabetes Registry [n= 6] 
and the Swedish National Diabetes Register [n= 4]). The review also identified several 
post-hoc analyses from clinical trials and large scale retrospective observational/
database analyses. Risk factors investigated included well characterized markers in 
T2D patients (e.g. HbA1c, blood pressure, lipids, proteinuria [n= 20]), less well char-
acterized factors including dietary components (n= 7), biochemical measures (e.g. 
serum uric acid, fibrinogen; n= 6), depression (n= 6) and poorly characterized risk 
factors including oral health (n= 1), erectile dysfunction (n= 1) and presence of H. pylori 
(n= 1). cOnclusiOns: Analysis of the literature showed that in addition to traditional 
risk markers, factors such as depression, erectile dysfunction, poor oral health are also 
independent risk factors for CV disease. These factors should be taken into account 
when estimating the CV risk profile for patients with T2D.
PCV31
RelatiOn Of the time in theRaPeUtiC Range (ttR) Of waRfaRin tO 
bleeding inCidenCeS in PatientS with atRial fibRillatiOn
Jasmi M.A.S.1, Mazlan M.N.1, Shaharuddin S.1, Zulkifly H.H.1, Long C.M.1, Hashim R.2, Abdul 
Wahab M.S.1
1Universiti Teknologi MARA, Selangor, Malaysia, 2Cyberjaya University College of Medical 
Sciences, Cyberjaya, Malaysia
Objectives: Warfarin use in atrial fibrillation has been established for preventing 
occurrence of stroke in patients with atrial fibrillation. However, safety and clinical 
monitoring of warfarin use is crucial due to its risk of bleeding complications. This 
study aims to compare and establish relation of time in therapeutic range (TTR) of 
warfarin in patients with atrial fibrillation in the first 6 months and 6 month thereaf-
ter of anticoagulation therapy. MethOds: This is a retrospective study carried out at 
a tertiary-care hospital with anticoagulation clinic in the state of Selangor, Malaysia. 
Data collected included patients’ demographics, co-morbidities, and international 
normalized ratio (INR). TTR were determined using Rosendaal method based on 
records found in database (INR Desk 4.0 system) and patients’ hemorrhage events 
were also recorded. Samples of the study were patient who started warfarin from 
January 2009 until March 2013. Results: A total of 167 patients with atrial fibrilla-
tion were enrolled and only 6% (n= 10) achieved TTR of more than 75% for the first 
6 months of warfarin use as compared to 16.8% (n= 28) of TTR more than 75% 6 
months thereafter. As for bleeding incidences, 29% (n= 45) of patients in the group 
of TTR less than 75% in the first 6 months had bleeding complications as compared 
to 18.7% (n= 26) in patients of TTR less than 75% 6 months after. cOnclusiOns: 
A more regular follow up is necessary during the first 6 months of new warfarin 
users as they tend to be out of the TTR and have a higher bleeding risk.
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ates the financial impact of apixaban introduction by comparing expected 1,2, and 
3 years costs in hypothetical scenarios: with and without apixaban. Italian NVAF 
patient population estimation is based on official apixaban reimbursement criteria, 
applying the characteristics of the trial population to national epidemiologic data. 
Sensitivity analysis is performed on an alternative non-experimental population of 
NVAF patients. Results: Among available NOACs, apixaban is expected to be the 
least expensive at 1,2, and 3 years in an estimated patient population of 364,000 
Italian patients, allowing for savings of over 5 million € by the third year. Results of 
the simulation run on an alternative non-experimental population of NVAF patients 
yields comparable estimates. Exclusive use of apixaban for three years in the identi-
fied population would allow for savings of € 8,832,500, € 14,446,551 and € 27,282,998 
when compared with dabigatran (110 mg), dabigatran (150 mg) and rivaroxaban, 
respectively. cOnclusiOns: The different safety and effectiveness profiles of the 
available NOACs emerging from the adjusted indirect comparison indicate that the 
introduction of apixaban could improve health care expenditure control while main-
taining or increasing therapeutic appropriateness in the Italian NVAF population.
PCV40
the bUdget imPaCt Of new geneRatiOn Ct SCanneRS fOR diffiCUlt-tO-
image, lOw-RiSk PatientS with SUSPeCted Cad
Shields G.E., Chapman A.M.
BresMed, Sheffield, UK
Objectives: The National Institute of Health and Care Excellence (NICE) issued 
diagnostic guidance on new generation computed tomography (CT) scanners rec-
ommending them as an option for the first-line imaging of coronary arteries in 
patients with suspected low-risk coronary artery disease (CAD) in whom imaging 
with old generation scanners is difficult (e.g. obese patients). The capital investment 
for a new generation scanner is considerably more than a standard scanner, which 
could hamper implementation. Based on the NICE guidance, a model was designed 
for use as a planning tool for rapid access chest pain clinics (RACPCs) looking to 
replace their current scanner with a new generation scanner. MethOds: An Excel® 
model was developed to estimate up to a 10-year impact of acquiring a new genera-
tion scanner. It was assumed that under standard care low-risk, difficult-to-image 
patients would be referred for a diagnostic invasive coronary angiography (ICA). 
Under the new diagnostic pathway these patients can be scanned with a new gener-
ation scanner. Whenever possible the NICE guidance was used to guide assumptions 
and populate default values. Results: The model estimates that for each difficult-
to-image patient a new generation scanner has the potential to save approximately 
£946.62 in diagnostic costs. Considering the capital investment required, a RACPC 
looking to replace their standard scanner and considering implementing a new 
generation CT scanner only need 53 difficult-to-image patients per year to see a 
positive return on investment over a 10-year period. cOnclusiOns: The model is 
likely to be conservative as it focuses on difficult-to-image patients only, yet the 
scanner is available for all patients who will likely benefit from the better sensitivity 
and specificity associated with the new scanners. However, it highlights that even 
a low number of these difficult-to-image patients will result in a positive return on 
investment over the expected life-time of the scanner.
PCV41
SimVaStatin PlUS fenOfibRate aS a fixed dOSe COmbinatiOn in the 
tReatment Of mixed dySliPidemia in gReeCe: bUdget imPaCt analySiS
Relakis J.1, Kourlaba G.2, Maniadakis N.1
1National School of Public Health, Athens, Greece, 2National and Kapodistrian University of 
Athens School of Medicine, Athens, Greece
Objectives: To evaluate the affordability of switching patients already treated with 
the multi-pill therapy of simvastatin and fenofibrate to the first simvastatin and 
fenofibrate fixed dosed combinations (FDC) product, for the management of mixed 
dyslipidemia in the Greek health care setting. MethOds: A budget impact model 
was locally adapted. The analysis was conducted from a third-party payer perspec-
tive over a time horizon of 3 years. The population with mixed dyslipidemia in 
Greece, the market shares of available treatments and the corresponding drug acqui-
sition costs were combined to estimate the total budgetary impact that will result 
from the penetration of FDC in the Greek market. Data on population with mixed 
dyslipidemia were derived from the National Statistical Service and published litera-
ture. Estimates of the current and future market shares were obtained from Abbott 
Hellas market research. Drug acquisition costs were calculated using the latest 
price bulletin issued and the corresponding reimbursement prices. Reimbursement 
prices were reduced by the patient’s relevant co-payment and relative rebates. Since 
market prices for the FDC are not available yet in Greece, estimated retail prices 
provided by Abbott Hellas were considered [FDC 20/145: € 13.70 (€ 12.22-16.27) and 
FDC 40/145: € 16.71 (€ 15.22-19.23)]. Results: Savings in pharmaceutical reimburse-
ment on year 1 were estimated at 146,974 (€ 181,084-€ 88,503) decreasing the relevant 
cost by 5.87% (7.23%-3.53%). On year 2, savings of € 250,544 (€ 322,536-€ 136,474) were 
attributed to the penetration of FDC, lowering the budget by 9.93% (12.78%-5.41%). 
On the 3rdyear, savings were estimated at € 403,405 (€ 509,489-€ 221,565) reducing 
spending by 15.82% (19.98%-8.69%). On average, over the 3-year time horizon of the 
analysis, the addition of FDC was found to decrease reimbursement costs by 10.54% 
(13.33%-5.88%) generating savings of € 266,974 (337,703€ -€ 148,147). cOnclusiOns: 
The introduction of FDC reimbursement will result in a predictable budget impact 
which is expected to decrease the relevant pharmaceutical cost for national health 
insurance.
PCV42
bUdget imPaCt analySiS Of bOtUlinUm tOxin a theRaPy fOR UPPeR limb 
SPaStiCity in geRmany
Zoellner Y.F.1, Gerwe M.2, Richter M.2
1Hamburg University of Applied Sciences, Hamburg, Germany, 2Ipsen Pharma, Ettlingen, Germany
Objectives: Upper limb spasticity (ULS) secondary to stroke has a considerable 
patient and caregiver burden, particularly with regards to pain, activities of daily 
quitting smoking. Cost of 5-year reimbursement varenicline was estimated to 
be € 63.0 millions, while smoking cessation avoided costs reached € 99.9 millions, 
which compared with € 21.1 millions savings in the not-reimbursed scenario: a net 
incremental cost-saving of € 15.9 millions. Savings were observed since 3rd year of 
modelling. cOnclusiOns: The BI of the reimbursement of varenicline in smoking 
cessation is a cost-effective health policy in the Spanish NHS, and could produce 
cost-savings since the 3rd year of implementation.
PCV37
bUdget imPaCt analySiS Of hyPeRtenSiVe tReatment with indaPamide 
and amlOdiPine Single-Pill COmbinatiOn in the POliSh Setting
Kawalec P.1, Stawowczyk E.2, Holko P.2, Borowiec L.3, Filipiak K.J.4
1Jagiellonian University Medical College, Krakow, Poland, 2Centrum HTA Sp z o. o. Sp. 
komandytowa, Kraków, Poland, 3Medical Department, Servier Poland Ltd, Warsaw, Poland, 41st 
Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
Objectives: The aim of this study was to calculate and compare public payer and 
patients’ costs of hypertensive treatment with indapamide 1.5 mg and amlodipine 
5 mg or 10 mg single-pill combination (SPC) and free combination (FC), in the Polish 
setting. MethOds: The analysis compared two scenarios: existing and new. The 
existing one assumed treatment with FC of indapamide 1.5 mg and amlodipine 5 
mg or 10 mg. The new one also included treatment with SPC of indapamide 1.5 mg 
+amlodipine 5/10 mg. Population and market shares were estimated on the basis of 
published reimbursement data, experts’ opinion and validated with available epide-
miological data. Cost data were analysed from the public payer perspective (National 
Health Fund) and from patient perspective, in a three-year horizon. SPC cost is based 
on average pharmacy price reported in April 2014 (18.13PLN and 19.75PLN respec-
tively for 1.5+5mg and 1.5+10mg /30 tabs); 30% patient copayment was assumed. 
The cost of FC was calculated as an average cost of reimbursed indapamide and 
amlodipine products in corresponding doses. All costs present 2014 values, and are 
expressed in Polish zloty (PLN). Average monthly exchange rate of May 2014 was 
applied (1EUR= 4.1790PLN). Difference in clinical effectiveness between SPC and FC 
was also included, in the form of cardiovascular events risk. Results: Introduction 
of indapamide/amlodipine SPC on the reimbursement list next to FC brought savings 
from public payer perspective and from patient perspective amounting to: 509,255PLN 
(121,860EUR) and 5,893,941PLN (1,410,371EUR) in first year, 689,239PLN (164,929EUR) 
and 7,833,005PLN (1,874,373EUR) in second year, 725,965PLN (173,717EUR) and 
8,328,480PLN (1,992,936EUR) in third year. Additionally it resulted in avoidance of 
808 cardiovascular events in the three-year horizon. cOnclusiOns: Treatment with 
indapamide/amlodipine SPC in comparison to FC generates significant savings both 
from the public payer perspective and from patient perspective in contemporary 
Polish setting, and reduces cardiovascular events.
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mOdeling the imPaCt Of a digital health feedbaCk SyStem in 
UnCOntROlled hyPeRtenSiVe PatientS
Kim Y.A., Virdhi N., Raja P., DiCarlo L.
Proteus Digital Health, Redwood City, CA, USA
Objectives: Despite the availability of numerous therapeutic agents and manage-
ment tools, half of all hypertensive patients do not have their blood pressure (BP) 
at goal. A model was developed to estimate the incremental costs of uncontrolled 
vs. controlled hypertension and the impact of shifting patients to controlled sta-
tus via a unique digital health feedback system. This Proteus system utilizes an 
Ingestible Sensor to determine medication-taking patterns, and a wearable 7-day 
sensor in the form of an adhesive patch to collect physiological and behavioral 
metrics such as heart rate, step count, and patterns of activity and rest, providing 
a means of determining non-response vs. non-adherence to prescribed medica-
tions and recommendations for daily routine. MethOds: The additional costs of 
outpatient services, monitoring, and cardiovascular complications were calculated 
for uncontrolled vs. controlled hypertensive patients from a US plan perspective for 
a 1 year time horizon. The clinical and utilization assumptions were derived from 
the literature and expert opinion, and costs were derived from the Medicare Fee 
Schedule and AHRQ databases. The impact of the Proteus system on BP control was 
based on a real-world study evaluating this technology in 164 patients with a history 
of uncontrolled hypertension. Results: In a health plan of 1 million members, 7.9% 
(78,656) were uncontrolled hypertensive patients receiving care who were eligible for 
the Proteus system. The direct annual medical costs of uncontrolled hypertension 
were estimated to be $60.9 million over the costs for controlled disease. The Proteus 
system was estimated to result in $7.3-18.3 million in savings ($328-$717 per BP at 
goal), and lead to a 3-9% reduction in the number of coronary artery disease and 
stroke events in one year. cOnclusiOns: Even in the short-term, a digital health 
feedback system appears to provide an effective way to mitigate the substantial 
costs of uncontrolled hypertension.
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Objectives: This study aims to perform a budget impact analysis of the use of three 
available novel oral anticoagulant agents (NOACs) for preventing thromboembolic 
events in Italian patients with non-valvular atrial fibrillation (NVAF). MethOds: 
Estimated Italian population of patients is run through a decision tree/Markov 
model simulating their treatment with the available therapeutic options: dabigatran 
at two dose levels (110 mg/bid for the over 80 years old, 150 mg/bid for younger NVAF 
patients), rivaroxaban, and apixaban. Effectiveness estimates derive from an adjusted 
indirect treatment comparison using warfarin as link. Epidemiological data and unit 
costs are collected from Italian published sources. The budget impact analysis evalu-
